Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
40 EVENTS
Founded DNH Chip Research Institute in Hodogaya-ku, Yokohama City, Kanagawa Prefecture (capital: 22 million yen), and started DNA chip research. Began joint research with Hitachi Software Engineering, Ltd. (now Hitachi Ltd.).
Founded DNH Chip Research Institute in 1999. Developed DNA chips that comprehensively detect gene expression, aiming to contribute to future diagnostics and drug discovery. Released various general-purpose chips starting with domestically produced yeast chips. Simultaneously promoted the development of analysis software and equipment, establishing a business based on product sales.
Started selling the first domestically produced general-purpose DNA chip "Yeast chip ver.1.0".
Relocated headquarters and consolidated research systems.
Relocated and consolidated headquarters to Tsurumi-ku, Yokohama City, in the "Yokohama Science Frontier" district.
Changed the company name to 'DNA Chip Research Institute Inc.'.
Started selling "AceGene Human Oligo Chip 30K".
Changed trade name to "DNA Chip Research Institute, Inc.".
Split one common stock into two (additional stocks due to split: 6,300 common stocks). Started selling "AceGene Mouse Oligo Chip 30K".
Listed on the Tokyo Stock Exchange Mothers Market.
Started selling "AceGene 30K on One Chip Version".
Split one common stock into two (additional stocks due to split: 13,600 common stocks).
Developed a new amino acid reagent and signed a licensing agreement with Sigma-Aldrich Japan Ltd.
Started selling "AceGene Premium Human".
Issued the first unsecured convertible bond with stock acquisition rights.
Formed a strategic alliance with U.S. Agilent Technologies Inc. in the DNA microarray business.
The full conversion of the first unsecured convertible bond with stock acquisition rights into shares has been completed.
Developed "ConPath Chip" and "ConPath Navigator" and started a new contract analysis business.
Started selling genetic analysis teaching materials "Hybrid Teacher" for school education.
"Probe Bank" received the Encouragement Award at the 24th Kanagawa Industrial Technology Development Award.
Transferred genome analysis business from Hubbit Genomics Inc. Started clinical trials for efficacy diagnosis of rheumatoid antibody drugs using RNA check. Started a breast cancer prognosis prediction testing service using "MammaPrint".
Certified for Privacy Mark.
Takeda Rika Industry Co., Ltd. formed a strategic partnership with U.S. WaferGeneBiosystems, Inc. Started exclusive domestic sales and contract services for next-generation ultra-high-speed ultra-sensitive real-time PCR device ("SmartChip").
Formed a business alliance with Riken Genesis Co., Ltd. for genetic analysis services.
Product announcement and sales start of clinical research gene expression database "iCIS-crdb".
Product announcement and sales start of rheumatoid arthritis interview system "iRIS" for clinical settings.
Product announcement and sales start of DNA extraction kit for hard tissues (teeth and bones) "TBONE EX KIT".
Split ordinary shares into 100 shares (additional shares due to split: 3,355,803 ordinary shares) and adopted a unit share system (unit share: 100 shares).
Formed a strategic partnership with U.S. Agilent Technologies Inc. for next-generation sequencing analysis business.
Changed stock listing market to Tokyo Stock Exchange Second Section.
Entered a capital and business alliance with Enplas Corporation (increased capital to 1.402 billion yen).
Relocated research facilities and offices to Minato Ward, Tokyo.
Transitioned from a company with audit & supervisory board to a company with an audit committee.
Dissolved the capital and business alliance contract with Enplas Corporation.
Formed a business alliance with Gene Metrics LLC on lung cancer compact panel business.
Established a medical laboratory in Kawasaki City, Kanagawa Prefecture.
Entered into a capital and business alliance agreement with Mitsui Chemicals, Inc.
Relocated the office to Kawasaki City, Kanagawa Prefecture.
The tender offer by Mitsui Chemicals, Inc. for our shares was successful.
Implemented a share consolidation through a tender offer. Transitioned from a company with an Audit and Supervisory Committee to a company with a Board of Auditors. Delisted from the Tokyo Stock Exchange Standard Market.
§07
News
23 ARTICLES
DNA Chip Laboratory Publishes Nanopore Sequencing Analysis Service
DNA Chip Laboratory offers a human whole-genome analysis service using nanopore sequencing. It can simultaneously obtain sequence and methylation information, enabling multi-faceted evaluation of analyses that were previously performed separately with a single sequencing dataset. It can also be used for structural variant and complex region analysis, supporting data acquisition tailored to research objectives.
On-Demand Release of Lung Cancer Online Seminar
The on-demand distribution of the online seminar "New Developments in Lung Cancer Companion Diagnostics: Considering Optimal Gene Testing and Treatment Choices", held on October 13, 2026, has begun. The distribution period is until November 30, 2026, and registration is required for viewing.
Notice of Restoration Work Due to PHP Vulnerability Response
From around 10:00 PM on October 21, our website was temporarily unavailable due to emergency maintenance by our server provider. It has now been restored and is available as usual. We apologize for any inconvenience caused to users.
Publication of Collaborative Research Paper on Long-Read Sequencing
The DNA Chip Research Institute published a collaborative research paper on long-read sequencing. The publication date is October 6, 2026.
Online Seminar: New Developments in Companion Diagnostics for Lung Cancer
An online seminar will be held on October 13, 2026, to discuss genetic testing and treatment strategies for lung cancer. The session will be chaired by Dr. Hisao Kasahara, and two presentations are planned. The seminar is also expected to be made available on demand afterward.
Notice of Transfer of Tbone EX Kit Business
DNA Chip Research Inc. announced that it will transfer its Tbone EX Kit business to Bio Dynamics Laboratory Inc., a subsidiary of Funakoshi Co., Ltd., effective October 5, 2026. Order acceptance will end with shipments scheduled for September 2026. For orders or inquiries from October onward, please contact the new distributor, Funakoshi Co., Ltd., or the new business operator, Bio Dynamics Laboratory Inc.
Online Seminar on Lung Cancer Genetic Testing
The online seminar scheduled for August 20, 2026, will discuss the latest trends and treatment strategies in genetic testing for lung cancer. Experts will explain the importance of genetic diagnosis and treatment for driver gene-positive lung cancer. Pre-registration is required, and on-demand streaming will be available later.
Start of Drug Addition Test for Lung Cancer Compact Panel
The DNA Chip Institute has expanded the indications for the Lung Cancer Compact Panel to include HER2 (ERBB2) gene mutations and has started testing. From August 3, 2026, we are offering tests with added new drugs.
Lung Cancer Compact Panel Drug Addition Testing Scheduled to Begin
DNA Chip Research Institute Inc. plans to add targeted drugs to the Lung Cancer Compact Panel and start testing from August 3, 2026. The HER2 (ERBB2) gene mutation will also be included as a target, expanding the number of applicable drugs. This will enable diagnosis with a broader range of anti-cancer agents.
Introduction to Agendia's MammaPrint webinar
The webinar, scheduled for July 24, 2026, will review the latest data and insights from MammaPrint that help predict chemotherapy and inform treatment decisions for early-stage HR+/HER2- breast cancer patients.